Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Regdanvimab: First Approval
Yahiya Y. Syed
Drugs (2021) Vol. 81, Iss. 18, pp. 2133-2137
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 214
Stopping pandemics before they start: Lessons learned from SARS-CoV-2
A.M. Edwards, Ralph S. Baric, Erica Ollmann Saphire, et al.
Science (2022) Vol. 375, Iss. 6585, pp. 1133-1139
Open Access | Times Cited: 85
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 78
Therapeutic monoclonal antibodies for COVID-19 management: an update
Vivek P. Chavda, Riddhi Prajapati, Disha Lathigara, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 6, pp. 763-780
Closed Access | Times Cited: 54
Therapeutic Antibodies in Medicine
Prerna Sharma, Rahul V. Joshi, Robert C. Pritchard, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6438-6438
Open Access | Times Cited: 29
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Enrique Míguez‐Rey, Dasom Choi, Seungmin Kim, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 1, pp. 41-58
Open Access | Times Cited: 37
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Engineering ACE2 decoy receptors to combat viral escapability
Takao Arimori, Nariko Ikemura, Toru Okamoto, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 10, pp. 838-851
Open Access | Times Cited: 32
SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy
Desh Deepak Singh, Anshul Sharma, Hae‐Jeung Lee, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 20
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Aline Almeida-Oliveira, Diana Freire, A. Andrade, et al.
Journal of Pharmaceutical Innovation (2023) Vol. 18, Iss. 3, pp. 1194-1212
Open Access | Times Cited: 12
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 4
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19
Arturo Casadevall, Scott A. McConnell, Daniele Focosi
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 787-797
Closed Access | Times Cited: 4
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development
Fabrizio Angius, Silvia Puxeddu, S Zaimi, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 17-17
Open Access | Times Cited: 4
Monoclonal antibodies – A repertoire of therapeutics
Suman Tapryal
Advances in protein chemistry and structural biology (2025), pp. 151-212
Closed Access
A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers
Thomas R. Moench, Lakshmi Botta, Brian T. Farrer, et al.
EBioMedicine (2025) Vol. 113, pp. 105582-105582
Closed Access
Development and validation of an LC–MS/MS method for pharmacokinetic assessment of a bispecific antibody (YBSW015) targeting SARS-CoV-2
Yuanyuan Chai, Ling Zhou, Yan Yang, et al.
Journal of Pharmaceutical and Biomedical Analysis (2025) Vol. 260, pp. 116770-116770
Closed Access
Empowering Healthcare with Phage Display Technology
Bin Lyu, Hangyu Zhou, Huijun Wang, et al.
ACS Biomaterials Science & Engineering (2025)
Closed Access
Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
Morgan D. McSweeney, Ian E. Stewart, Zach Richardson, et al.
Bioengineering & Translational Medicine (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 14
Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
Sun In Hong, Byung-Han Ryu, Kyung‐Wook Hong, et al.
Infection and Chemotherapy (2022) Vol. 54, Iss. 1, pp. 114-114
Open Access | Times Cited: 13
Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?
Yadira Palacios, Leslie Chávez‐Galán
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 616-616
Open Access | Times Cited: 11
Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
Young Rock Jang, Yoon Ju Oh, Jin Yong Kim
International Journal of Infectious Diseases (2023) Vol. 130, pp. 94-100
Open Access | Times Cited: 5
Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
Mingyang Yang, Toni Li, Lihai Jiang, et al.
Journal of Infection (2022) Vol. 85, Iss. 4, pp. e122-e124
Open Access | Times Cited: 8
Synthetic α‐Helical Peptides as Potential Inhibitors of the ACE2 SARS‐CoV‐2 Interaction
Pascal M. Engelhardt, Sebastián Florez‐Rueda, Marco Drexelius, et al.
ChemBioChem (2022) Vol. 23, Iss. 17
Open Access | Times Cited: 8
Druggable targets and therapeutic development for COVID-19
Xiaohua Duan, Lauretta A. Lacko, Shuibing Chen
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top